Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles

Human Gene Therapy

Volumn 27, Issue 10, 2016, Pages 729-740

  Yu, Kyung Rok ^a   Natanson, Hannah ^a   Dunbar, Cynthia E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; CELL PROLIFERATION; CELL SPECIFICITY; CYTOTOXICITY; DNA DAMAGE; DNA TRANSFECTION; GENE EDITING; GENETIC PROCEDURES; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; REVIEW; RNA TRANSFECTION; STEM CELL SELF-RENEWAL; VIRAL GENE DELIVERY SYSTEM; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENE THERAPY; GENE VECTOR; GENETICS; HEMATOLOGIC DISEASE; HUMAN GENOME; PROCEDURES; STEM CELL; STEM CELL TRANSPLANTATION;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENE EDITING; GENETIC THERAPY; GENETIC VECTORS; GENOME, HUMAN; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELLS; HUMANS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84989245365     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.107     Document Type: Review

References (72)

1. Williams DA, Lemischka IR, Nathan DG, et al. Introduction of new genetic material into pluripotent hematopoietic stem-cells of the mouse. Nature 1984;310:476-480.
2. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-672.
3. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363: 355-364.
4. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360: 447-458.
5. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010;363: 1918-1927.
6. Naldini L. Gene therapy returns to centre stage. Nature 2015;526:351-360.
7. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142.
8. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118:3143-3150.
9. Baldo A, van den Akker E, Bergmans HE, et al. General considerations on the biosafety of virusderived vectors used in gene therapy and vaccination. Curr Gene Ther 2013;13:385-394.
10. Yamashita M, Emerman M. Retroviral infection of non-dividing cells: old and new perspectives. Virology 2006;344:88-93.
11. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-529.
12. Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr Gene Ther 2011;11: 218-228.
13. Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest 2014;124:4154-4161.
14. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science 2009;326:1501.
15. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005;435:646-651.
16. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014;15:321-334.
17. Liu J, Gaj T, Yang Y, et al. Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells. Nat Protoc 2015; 10:1842-1859.
18. Cho SW, Kim S, Kim JM, et al. Targeted genome engineering in human cells with the Cas9 RNAguided endonuclease. Nat Biotechnol 2013;31: 230-232.
19. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819-823.
20. Hwang WY, Fu Y, Reyon D, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013;31:227-229.
21. Jiang W, Bikard D, Cox D, et al. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013;31:233-239.
22. Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337:816-821.
23. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 D32/D32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
24. Bauer DE, Orkin SH. Hemoglobin switching's surprise: The versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev 2015;33:62-70.
25. Segal DJ, Goncalves J, Eberhardy S, et al. Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem 2004;279:14509-14519.
26. Heckl D, Kowalczyk MS, Yudovich D, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 2014;32: 941-946.
27. Yu KR, Corat MAF, Metais JY, et al. The cytotoxic effect of RNA-guided endonuclease Cas9 on human hematopoietic stem and progenitor cells (HSPCs). Mol Ther 2016;24:S225-S226.
28. Gaj T, Guo J, Kato Y, et al. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods 2012;9:805-807.
29. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: A slow coming of age. Mol Ther 2009;17:1316-1332.
30. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007;25: 1298-1306.
31. Joglekar AV, Hollis RP, Kuftinec G, et al. Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol Ther 2013;21: 1705-1717.
32. Li LJ, Krymskaya L, Wang JB, et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 2013;21:1259-1269.
33. Saydaminova K, Ye X, Wang H, et al. Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under micro-RNA regulation. Mol Ther Methods Clin Dev 2015;1:14057.
34. Hastie E, Samulski RJ. Adeno-associated virus at 50: A golden anniversary of discovery, research, and gene therapy success-a personal perspective. Hum Gene Ther 2015;26:257-265.
35. Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016;351:403-407.
36. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015;520:186-191.
37. Wang J, Exline CM, DeClercq JJ, et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 2015;33:1256-1263.
38. Buechele C, Breese EH, Schneidawind D, et al. MLL leukemia induction by genome editing of human CD34+ hematopoietic cells. Blood 2015;126: 1683-1694.
39. Mandal PK, Ferreira LM, Collins R, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014;15:643-652.
40. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zincfinger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28:839-847.
41. Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther 2016;24:430-446.
42. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014;510: 235-240.
43. De Ravin SS, Reik A, Liu PQ, et al. Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol 2016;34:424-429.
44. Peterson CW, Wang J, Norman KK, et al. Longterm multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates. Blood 2016;127:2416-2426.
45. Chang KH, Sullivan T, Liu M, et al. Clonal analysis of human bone marrow CD34+ cells edited by BCL11A-targeting zinc finger nucleases reveals clinically relevant levels of fetal globin expression in edited erythroid progeny. Blood 2015;126.
46. Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 2015;33:985-989.
47. Liang X, Potter J, Kumar S, et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol 2015;208: 44-53.
48. Schiroli G, Genovese P, Capo V, et al. Targeted genome editing in mouse hematopoietic stem/ progenitor cells (HSPC) to model gene correction of SCID-X1. Hum Gene Ther 2015;26: A8-A8.
49. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 2015;125: 2597-2604.
50. DeWitt M, Magis W, Bray NL, et al. Efficient correction of the sickle mutation in human hematopoietic stem cells using a Cas9 ribonucleoprotein complex. bioRxiv (in press). Preprint available from: http://biorxiv. org/content/early/ 2016/01/15/036236
51. Weinstock DM, Richardson CA, Elliott B, et al. Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair (Amst) 2006;5:1065-1074.
52. Miller JC, Holmes MC, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007;25: 778-785.
53. Miller JC, Zhang L, Xia DF, et al. Improved specificity of TALE-based genome editing using an expanded RVD repertoire. Nat Methods 2015;12: 465-471.
54. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med 2015; 21:121-131.
55. Fu Y, Sander JD, Reyon D, et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 2014;32: 279-284.
56. Cho SW, Kim S, Kim Y, et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 2014;24: 132-141.
57. Ran FA, Hsu PD, Lin CY, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013;154:1380-1389.
58. Mali P, Aach J, Stranges PB, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 2013;31:833-838.
59. Kim D, Kim J, Hur JK, et al. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol 2016;34: 863-868.
60. Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 2015;163:759-771.
61. Peters W, Dupuis M, Charo IF. A mechanism for the impaired IFN-c production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses. J Immunol 2000;165:7072-7077.
62. Smith MW, Carrington M, Winkler C, et al. CCR2 chemokine receptor and AIDS progression. Nat Med 1997;3:1052-1053.
63. Gabriel R, Lombardo A, Arens A, et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 2011;29: 816-823.
64. Corrigan-Curay J, O'Reilly M, Kohn DB, et al. Genome editing technologies: defining a path to clinic. Mol Ther 2015;23:796-806.
65. Tsai SQ, Zheng Z, Nguyen NT, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 2015; 33:187-197.
66. Milyavsky M, Gan OI, Trottier M, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosisindependent role for p53 in self-renewal. Cell Stem Cell 2010;7:186-197.
67. Porteus MH. Towards a new era in medicine: Therapeutic genome editing. Genome Biol 2015;16:286.
68. Mezquita P, Beard BC, Kiem HP. NOD/SCID repopulating cells contribute only to short-term repopulation in the baboon. Gene Ther 2008;15: 1460-1462.
69. McDermott SP, Eppert K, Lechman ER, et al. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 2010;116:193-200.
70. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011;12: 301-315.
71. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-910.
72. Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome-edited T-cell manufacturing platform for ''off-the-shelf'' adoptive T-cell immunotherapies. Cancer Res 2015;75:3853-3864.